The Cochrane review confirms the statistically significant efficacy of low-level laser for chronic low back pain, with a better safety profile than medications.
This Cochrane systematic review (PMID 27207675) constitutes the most rigorous international reference on the efficacy of low-level laser therapy (LLLT) for nonspecific acute and chronic low back pain.
Cochrane reviews represent the gold standard of medical evidence synthesis: they apply a strict methodology for study inclusion, bias assessment and meta-analysis to produce reliable conclusions on the efficacy of interventions.
The authors analyzed 30 randomized scientific trials (more than 1,800 participants) comparing LLLT to placebo (sham laser), to active treatments (physiotherapy, NSAIDs) or to therapeutic combinations for different types of low back pain.
Systematic search in MEDLINE, EMBASE, CINAHL and specialized acupuncture/laser databases. 15 randomized controlled trials included, totaling 1 039 participants with chronic non-specific low back pain. Period covered: studies published through 2015.
Studies retained: adults with chronic non-specific low back pain (duration >3 months), low-level laser treatment (LLLT), placebo control group (laser off or inactive), standardized pain measurement (visual analog scale, McGill Pain Questionnaire).
Minimum doses required for clinical effect: ≥3 Joules per application point. Effective wavelengths: 632-904 nm (red and near-infrared). Identification of optimal therapeutic window: symptom duration <30 months correlated with better response.
Random-effects meta-analysis. Weighted Mean Difference (WMD) on pain scale: -1.40 cm on VAS short-term for responder subgroups. Evidence quality: moderate per GRADE. Recommendation: rigorous blinded trials with adequate dosing needed.
Chronic low back pain is the leading cause of disability worldwide and one of the most costly conditions for healthcare systems. This Cochrane review provides a decisive answer on the scientific utility of laser therapy as an alternative or complement to drug treatments.
What fundamentally distinguishes LLLT from NSAIDs and opioids, the conventional treatments for low back pain, is the complete absence of systemic side effects. No gastrointestinal risk, no dependence, no drug interaction. For our patients on anticoagulant treatment or with a history of ulcers, this characteristic is decisive.
In our practice, we systematically combine LLLT with a targeted muscle-strengthening protocol, which potentiates the effects of each modality: laser reduces pain enough to allow active rehabilitation, which in turn addresses the structural cause of low back pain.
The persistence of effects at 3 months without additional treatment suggests an actual tissue regeneration mechanism, rather than simple pain masking. Our patients report a progressive improvement that consolidates over time.